Motor and nonmotor complications in Parkinson's disease

An argument for continuous drug delivery?

K. Ray Chaudhuri, Alexandra Rizos, Kapil Dev Sethi

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The complications of long-term levodopa therapy for Parkinson's disease (PD) include motor fluctuations, dyskinesias, and also nonmotor fluctuations - at least equally common, but less well appreciated - in autonomic, cognitive/psychiatric, and sensory symptoms. In seeking the pathophysiologic mechanisms, the leading hypothesis is that in the parkinsonian brain, intermittent, nonphysiological stimulation of striatal dopamine receptors destabilizes an already unstable system. Accordingly, a major goal of PD treatment in recent years has been the attainment of continuous dopaminergic stimulation (CDS) - or, less theoretically (and more clinically verifiable), continuous drug delivery (CDD). Improvements in the steadiness of the plasma profiles of various dopaminergic therapies may be a signal of progress. However, improvements in plasma profile do not necessarily translate into CDS, or even into CDD to the brain. Still, it is reassuring that clinical studies of approaches to CDD have generally been positive. Head-to-head comparative trials have often failed to uncover evidence favoring such approaches over an intermittent therapy. Nevertheless, the findings among recipients of subcutaneous apomorphine infusion or intrajejunal levodopa/carbidopa intestinal gel suggest that nonmotor PD symptoms or complications may improve in tandem with motor improvement. In vivo receptor binding studies may help to determine the degree of CDS that a dopaminergic therapy can confer. This may be a necessary first step toward establishing whether CDS is, in fact, an important determinant of clinical efficacy. Certainly, the complexities of optimal PD management, and the rationale for an underlying strategy such as CDS or CDD, have not yet been thoroughly elucidated.

Original languageEnglish (US)
Pages (from-to)1305-1320
Number of pages16
JournalJournal of Neural Transmission
Volume120
Issue number9
DOIs
StatePublished - Sep 1 2013

Fingerprint

Parkinson Disease
Pharmaceutical Preparations
Therapeutics
Corpus Striatum
Subcutaneous Infusions
Apomorphine
Dyskinesias
Dopamine Receptors
Brain
Levodopa
Disease Management
Psychiatry
Gels

Keywords

  • Continuous drug delivery
  • Motor complications
  • Nonmotor fluctuations
  • Parkinson's disease

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Motor and nonmotor complications in Parkinson's disease : An argument for continuous drug delivery? / Chaudhuri, K. Ray; Rizos, Alexandra; Sethi, Kapil Dev.

In: Journal of Neural Transmission, Vol. 120, No. 9, 01.09.2013, p. 1305-1320.

Research output: Contribution to journalArticle

Chaudhuri, K. Ray ; Rizos, Alexandra ; Sethi, Kapil Dev. / Motor and nonmotor complications in Parkinson's disease : An argument for continuous drug delivery?. In: Journal of Neural Transmission. 2013 ; Vol. 120, No. 9. pp. 1305-1320.
@article{f55ab6966cce4e55b26527d8faec8ab4,
title = "Motor and nonmotor complications in Parkinson's disease: An argument for continuous drug delivery?",
abstract = "The complications of long-term levodopa therapy for Parkinson's disease (PD) include motor fluctuations, dyskinesias, and also nonmotor fluctuations - at least equally common, but less well appreciated - in autonomic, cognitive/psychiatric, and sensory symptoms. In seeking the pathophysiologic mechanisms, the leading hypothesis is that in the parkinsonian brain, intermittent, nonphysiological stimulation of striatal dopamine receptors destabilizes an already unstable system. Accordingly, a major goal of PD treatment in recent years has been the attainment of continuous dopaminergic stimulation (CDS) - or, less theoretically (and more clinically verifiable), continuous drug delivery (CDD). Improvements in the steadiness of the plasma profiles of various dopaminergic therapies may be a signal of progress. However, improvements in plasma profile do not necessarily translate into CDS, or even into CDD to the brain. Still, it is reassuring that clinical studies of approaches to CDD have generally been positive. Head-to-head comparative trials have often failed to uncover evidence favoring such approaches over an intermittent therapy. Nevertheless, the findings among recipients of subcutaneous apomorphine infusion or intrajejunal levodopa/carbidopa intestinal gel suggest that nonmotor PD symptoms or complications may improve in tandem with motor improvement. In vivo receptor binding studies may help to determine the degree of CDS that a dopaminergic therapy can confer. This may be a necessary first step toward establishing whether CDS is, in fact, an important determinant of clinical efficacy. Certainly, the complexities of optimal PD management, and the rationale for an underlying strategy such as CDS or CDD, have not yet been thoroughly elucidated.",
keywords = "Continuous drug delivery, Motor complications, Nonmotor fluctuations, Parkinson's disease",
author = "Chaudhuri, {K. Ray} and Alexandra Rizos and Sethi, {Kapil Dev}",
year = "2013",
month = "9",
day = "1",
doi = "10.1007/s00702-013-0981-5",
language = "English (US)",
volume = "120",
pages = "1305--1320",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Motor and nonmotor complications in Parkinson's disease

T2 - An argument for continuous drug delivery?

AU - Chaudhuri, K. Ray

AU - Rizos, Alexandra

AU - Sethi, Kapil Dev

PY - 2013/9/1

Y1 - 2013/9/1

N2 - The complications of long-term levodopa therapy for Parkinson's disease (PD) include motor fluctuations, dyskinesias, and also nonmotor fluctuations - at least equally common, but less well appreciated - in autonomic, cognitive/psychiatric, and sensory symptoms. In seeking the pathophysiologic mechanisms, the leading hypothesis is that in the parkinsonian brain, intermittent, nonphysiological stimulation of striatal dopamine receptors destabilizes an already unstable system. Accordingly, a major goal of PD treatment in recent years has been the attainment of continuous dopaminergic stimulation (CDS) - or, less theoretically (and more clinically verifiable), continuous drug delivery (CDD). Improvements in the steadiness of the plasma profiles of various dopaminergic therapies may be a signal of progress. However, improvements in plasma profile do not necessarily translate into CDS, or even into CDD to the brain. Still, it is reassuring that clinical studies of approaches to CDD have generally been positive. Head-to-head comparative trials have often failed to uncover evidence favoring such approaches over an intermittent therapy. Nevertheless, the findings among recipients of subcutaneous apomorphine infusion or intrajejunal levodopa/carbidopa intestinal gel suggest that nonmotor PD symptoms or complications may improve in tandem with motor improvement. In vivo receptor binding studies may help to determine the degree of CDS that a dopaminergic therapy can confer. This may be a necessary first step toward establishing whether CDS is, in fact, an important determinant of clinical efficacy. Certainly, the complexities of optimal PD management, and the rationale for an underlying strategy such as CDS or CDD, have not yet been thoroughly elucidated.

AB - The complications of long-term levodopa therapy for Parkinson's disease (PD) include motor fluctuations, dyskinesias, and also nonmotor fluctuations - at least equally common, but less well appreciated - in autonomic, cognitive/psychiatric, and sensory symptoms. In seeking the pathophysiologic mechanisms, the leading hypothesis is that in the parkinsonian brain, intermittent, nonphysiological stimulation of striatal dopamine receptors destabilizes an already unstable system. Accordingly, a major goal of PD treatment in recent years has been the attainment of continuous dopaminergic stimulation (CDS) - or, less theoretically (and more clinically verifiable), continuous drug delivery (CDD). Improvements in the steadiness of the plasma profiles of various dopaminergic therapies may be a signal of progress. However, improvements in plasma profile do not necessarily translate into CDS, or even into CDD to the brain. Still, it is reassuring that clinical studies of approaches to CDD have generally been positive. Head-to-head comparative trials have often failed to uncover evidence favoring such approaches over an intermittent therapy. Nevertheless, the findings among recipients of subcutaneous apomorphine infusion or intrajejunal levodopa/carbidopa intestinal gel suggest that nonmotor PD symptoms or complications may improve in tandem with motor improvement. In vivo receptor binding studies may help to determine the degree of CDS that a dopaminergic therapy can confer. This may be a necessary first step toward establishing whether CDS is, in fact, an important determinant of clinical efficacy. Certainly, the complexities of optimal PD management, and the rationale for an underlying strategy such as CDS or CDD, have not yet been thoroughly elucidated.

KW - Continuous drug delivery

KW - Motor complications

KW - Nonmotor fluctuations

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84883455518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883455518&partnerID=8YFLogxK

U2 - 10.1007/s00702-013-0981-5

DO - 10.1007/s00702-013-0981-5

M3 - Article

VL - 120

SP - 1305

EP - 1320

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 9

ER -